

# Jia Fan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/75905/jia-fan-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

394  
papers

15,954  
citations

60  
h-index

115  
g-index

440  
ext. papers

21,156  
ext. citations

7.2  
avg, IF

6.4  
L-index

#	Paper	IF	Citations
394	Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma.. <i>Annals of Translational Medicine</i> , <b>2022</b> , 10, 394	3.2	0
393	CircRPN2 inhibits aerobic glycolysis and metastasis in hepatocellular carcinoma.. <i>Cancer Research</i> , <b>2022</b> ,	10.1	5
392	High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.. <i>Journal of Clinical Laboratory Analysis</i> , <b>2022</b> , e24259	2.59	3
391	Spatial omics: Navigating to the golden era of cancer research.. <i>Clinical and Translational Medicine</i> , <b>2022</b> , 12, e696	5.7	1
390	MCT4 inhibition potentiates hepatocellular carcinoma immunotherapy via enhancing T cell infiltration and immune attack.. <i>Hepatology</i> , <b>2022</b> ,	11.2	3
389	Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence.. <i>Signal Transduction and Targeted Therapy</i> , <b>2022</b> , 7, 24	21	0
388	AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS488-TPS488	2.2	
387	The treatment strategy and outcome for spontaneously ruptured hepatocellular carcinoma: a single-center experience in 239 patients.. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2022</b> , 1	4.9	0
386	Exosome-depleted MiR-148a-3p derived from Hepatic Stellate Cells Promotes Tumor Progression via ITGA5/PI3K/Akt Axis in Hepatocellular Carcinoma.. <i>International Journal of Biological Sciences</i> , <b>2022</b> , 18, 2249-2260	11.2	3
385	Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma.. <i>Nature Communications</i> , <b>2022</b> , 13, 1642	17.4	2
384	Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 847263	8.4	
383	KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma.. <i>Cancer Cell International</i> , <b>2022</b> , 22, 128	6.4	0
382	Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 831101	8.4	0
381	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).. <i>Hepatobiliary Surgery and Nutrition</i> , <b>2022</b> , 11, 227-252	2.1	0
380	CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis.. <i>Clinical and Translational Medicine</i> , <b>2022</b> , 12, e794	5.7	2
379	Changing epidemiology of hepatocellular carcinoma in Asia.. <i>Liver International</i> , <b>2022</b> ,	7.9	5
378	CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma.. <i>Cell Death and Disease</i> , <b>2022</b> , 13, 331	9.8	0

377	Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma Single-Cell Analysis.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 871769	8.4	0
376	Start of an era: circulating cell-free DNA for early detection of cancers. <i>Innovation(China)</i> , <b>2022</b> , 100259	17.8	0
375	Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus. <i>Gut</i> , <b>2021</b> , 70, 2159-2171	19.2	8
374	DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury. <i>Cellular and Molecular Immunology</i> , <b>2021</b> , 18, 1718-1728	15.4	11
373	Ultra-Sensitive and Affordable Assay for Early Detection of Primary Liver Cancer Using Plasma cfDNA Fragmentomics.. <i>Hepatology</i> , <b>2021</b> ,	11.2	5
372	Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. <i>Gut</i> , <b>2021</b> , 70, 951-961	19.2	16
371	Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , <b>2021</b> ,	5.4	3
370	TM2D1 contributes the epithelial-mesenchymal transition of hepatocellular carcinoma via modulating AKT/βcatenin axis. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 1557-1571	4.4	1
369	BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 2044-2061	4.4	
368	Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 200	22.4	2
367	Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
366	Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.. <i>Cancer Cell</i> , <b>2021</b> ,	24.3	7
365	Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation. <i>Journal of Cancer</i> , <b>2021</b> , 12, 7190-7200	4.5	1
364	Mucin 1 promotes tumor progression through activating WNT/βcatenin signaling pathway in intrahepatic cholangiocarcinoma. <i>Journal of Cancer</i> , <b>2021</b> , 12, 6937-6947	4.5	1
363	The progress of immune checkpoint therapy in primary liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2021</b> , 1876, 188638	11.2	2
362	Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX-i120 Platform: A prospective study. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2345-2362	7.9	3
361	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. <i>Liver Cancer</i> , <b>2021</b> , 10, 320-329	9.1	13
360	Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 14	9.8	4

359	Quantitative acetylome analysis reveals histone modifications that may predict prognosis in hepatitis B-related hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e313	5.7	5
358	PNOX Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 647209	8.4	4
357	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. <i>Biomarker Research</i> , <b>2021</b> , 9, 19	8	10
356	Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3 <b>2021</b> , 9,		9
355	Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 260	9.8	12
354	Development and Validation of a Nomogram Based on Perioperative Factors to Predict Post-hepatectomy Liver Failure. <i>Journal of Clinical and Translational Hepatology</i> , <b>2021</b> , 9, 291-300	5.2	2
353	Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 3757-3767	4.9	12
352	The diagnostic value of plasma exosomal for hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 359-371	2.3	9
351	Laparoscopic vs. Open Repeat Hepatectomy for Recurrent Liver Tumors: A Propensity Score-Matched Study and Meta-Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 646737	5.3	2
350	Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 652	3.2	6
349	Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16144-e16144	2.2	0
348	Simulation of portal/hepatic vein associated remnant liver ischemia/congestion by three-dimensional visualization technology based on preoperative CT scan. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 756	3.2	1
347	Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction. <i>Surgical Innovation</i> , <b>2021</b> , 15533506211018620	2	
346	A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 774	3.2	1
345	CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. <i>Molecular Cancer</i> , <b>2021</b> , 20, 75	42.1	10
344	Development of an Eight-gene Prognostic Model for Overall Survival Prediction in Patients with Hepatocellular Carcinoma.. <i>Journal of Clinical and Translational Hepatology</i> , <b>2021</b> , 9, 898-908	5.2	
343	Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4099-4099	2.2	1
342	Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4094-4094	2.2	3

341	Analysis of epigenomic signatures in cell-free DNA (cfDNA) from cancer patients and high-risk controls: A blinded test cohort of THUNDER-II study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e22518-e22518	2.3	0
340	Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16163-e16163	2.2	0
339	A Semi-Automatic Step-by-Step Expert-Guided LI-RADS Grading System Based on Gadoxetic Acid-Enhanced MRI. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 671-683	5.3	0
338	Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma. <i>Aging</i> , <b>2021</b> , 13, 151265-151383	5.1	3
337	BRG1 regulates lipid metabolism in hepatocellular carcinoma through the PIK3AP1/PI3K/AKT pathway by mediating GLMP expression. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	1
336	Newly detected liver nodules with a history of colorectal cancer: are they metastatic? Review of 2,632 cases in a single center. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 1079	3.2	0
335	Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 704042	5.3	0
334	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. <i>Nature Communications</i> , <b>2021</b> , 12, 4091	17.4	13
333	Laparoscopic hepatectomy enhances recovery for small hepatocellular carcinoma with liver cirrhosis by postoperative inflammatory response attenuation: a propensity score matching analysis with a conventional open approach. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2021</b> , 35, 910-920	5.2	2
332	Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. <i>Liver International</i> , <b>2021</b> , 41, 562-573	7.9	8
331	Splicing factors: Insights into their regulatory network in alternative splicing in cancer. <i>Cancer Letters</i> , <b>2021</b> , 501, 83-104	9.9	7
330	Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. <i>Cell</i> , <b>2021</b> , 184, 404-423	16.1	96
329	Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. <i>Liver Transplantation</i> , <b>2021</b> , 27, 444-449	4.5	7
328	BACH2-mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL. <i>Cancer Science</i> , <b>2021</b> , 112, 1235-1250	6.9	3
327	Factors influencing adjuvant treatment decision making among Chinese patients with hepatocellular carcinoma (HCC): Results of a patient survey.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 346-346	3.2	1
326	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e335	5.7	7
325	Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. <i>Hepatobiliary and Pancreatic Diseases International</i> , <b>2021</b> , 20, 13-20	2.1	5
324	miRNA-mRNA Regulatory Network and Factors Associated with Prediction of Prognosis in Hepatocellular Carcinoma. <i>Genomics, Proteomics and Bioinformatics</i> , <b>2021</b> ,	6.5	7

323	A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	4
322	CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression. <i>Carcinogenesis</i> , <b>2021</b> , 42, 1293-1303	4.6	3
321	Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 977-990	31.7	69
320	Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	17
319	CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 705378	8.4	1
318	Cystathionine Synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis <b>2021</b> , 9,		5
317	Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma. <i>Molecular Therapy</i> , <b>2021</b> ,	11.7	2
316	Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma. <i>Hepatology</i> , <b>2021</b> ,	11.2	1
315	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. <i>Molecular Oncology</i> , <b>2021</b> ,	7.9	2
314	Sintilimab plus IBI305 for hepatocellular carcinoma - Author's reply. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e388-1.7		
313	Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 58	3.2	1
312	110. A Phase 3, Multicenter, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infections. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S67-S68	1	
311	CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF- $\kappa$ B oncogenic signaling. <i>Clinical and Translational Medicine</i> , <b>2020</b> , 10, e233	5.7	19
310	Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. <i>Cell Discovery</i> , <b>2020</b> , 6, 90	22.3	17
309	Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. <i>Molecular Cancer</i> , <b>2020</b> , 19, 92	42.1	62
308	Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. <i>Signal Transduction and Targeted Therapy</i> , <b>2020</b> , 5, 56	21	21
307	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 92-100	8.7	5
306	Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. <i>Theranostics</i> , <b>2020</b> , 10, 6530-6543	12.1	11

305	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 487	3.2	6
304	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. <i>Cancer Cytopathology</i> , <b>2020</b> , 128, 733-745	3.9	6
303	The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. <i>Clinical and Translational Medicine</i> , <b>2020</b> , 10, 45-56	5.7	12
302	A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. <i>Surgery</i> , <b>2020</b> , 167, 926-932	3.6	3
301	MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. <i>Journal of Cancer</i> , <b>2020</b> , 11, 2476-2484	4.5	8
300	Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , <b>2020</b> , 11, 112-120	2.8	1
299	miR-17-5p and miR-20a-5p suppress postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3-NF- $\kappa$ B positive feedback loop. <i>Theranostics</i> , <b>2020</b> , 10, 3668-3683	12.1	26
298	Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases. <i>Hepatology International</i> , <b>2020</b> , 14, 437-453	8.8	15
297	Autoantibody signature in hepatocellular carcinoma using seromics. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 85	22.4	10
296	MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 12	22.4	25
295	A retrospective cohort study of preoperative lipid indices and their impact on new-onset diabetes after liver transplantation. <i>Journal of Clinical Laboratory Analysis</i> , <b>2020</b> , 34, e23192	3	3
294	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 955-966	3.6	7
293	Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-ROR $\alpha$ Wnt/ECatenin axis. <i>Cancer Letters</i> , <b>2020</b> , 476, 140-151	9.9	17
292	Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS -applied prediction model. <i>Cancer Science</i> , <b>2020</b> , 111, 1084-1092	6.9	7
291	ROR- $\beta$ 1 inhibits the proliferation, invasion, and migration of hepatocellular carcinoma MHCC97H via downregulation of chemokine CXCL5. <i>Cytokine</i> , <b>2020</b> , 129, 155004	4	7
290	Comparison of immune profiles between hepatocellular carcinoma subtypes. <i>Biophysics Reports</i> , <b>2020</b> , 6, 19-32	3.5	1
289	Enhancing soluble expression of sucrose phosphorylase in Escherichia coli by molecular chaperones. <i>Protein Expression and Purification</i> , <b>2020</b> , 169, 105571	2	8
288	Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis. <i>Molecular Metabolism</i> , <b>2020</b> , 36, 100966	8.8	8

287	Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis. <i>BioMed Research International</i> , <b>2020</b> , 2020, 6784138	3	5
286	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). <i>Liver Cancer</i> , <b>2020</b> , 9, 682-720	9.1	108
285	Development of a novel liquid biopsy test to diagnose and locate gastrointestinal cancers.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1557-1557	2.2	1
284	Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4592-4592	2.2	2
283	Genome-wide plasma cell-free DNA methylation profiling to identify high-performing biomarkers for early detection of hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4600-4600	2.2	1
282	Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16610-e16610	2.2	2
281	Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16690-e16690	2.2	5
280	Effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion: A phase II study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 514-514	2.2	1
279	Integrated Bioinformatics analysis and clinical validation reveals that high expression of mucin 1 in intrahepatic cholangiocarcinoma predicts recurrence after curative resection. <i>Experimental and Therapeutic Medicine</i> , <b>2020</b> , 20, 50	2.1	1
278	GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , <b>2020</b> , 10, 3705-3720	4.4	4
277	Integrated Bioinformatics analysis and clinical validation reveals that high expression of mucin 1 in intrahepatic cholangiocarcinoma predicts recurrence after curative resection. <i>Experimental and Therapeutic Medicine</i> , <b>2020</b> , 20, 1-1	2.1	1
276	Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 204	3.2	10
275	C5aR correlated with the dissemination capacity of circulating tumor cells in hepatocellular carcinoma by targeting INHBA-p-smad2/3-EMT/MMPs axis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16649-e16649	3.2	0
274	Autophagy and Liver Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1207, 497-528	3.6	3
273	Landscape and Regulation of mA and mAm Methylome across Human and Mouse Tissues. <i>Molecular Cell</i> , <b>2020</b> , 77, 426-440.e6	17.6	77
272	Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 896-908	13.4	48
271	Circular RNA Sequencing Identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis. <i>Hepatology</i> , <b>2020</b> , 72, 906-922	11.2	99
270	TGM3 promotes epithelial-mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 668-676	3.3	8



269	Reply to 'Are the 5-hydroxymethylcytosine-based wd-scores really superior over Eftoprotein for the early diagnosis of hepatocellular carcinoma?'. <i>Gut</i> , <b>2020</b> , 69, 1903-1904	19.2	2
268	Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. <i>Clinica Chimica Acta</i> , <b>2020</b> , 511, 67-74	6.2	5
267	Tfr-Tfh index: A new predictor for recurrence of hepatocellular carcinoma patients with HBV infection after curative resection. <i>Clinica Chimica Acta</i> , <b>2020</b> , 511, 282-290	6.2	1
266	DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , <b>2020</b> , 18, 176	3.4	9
265	Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , <b>2020</b> , 19, 1533033820937002	2.7	0
264	Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. <i>BMC Cancer</i> , <b>2020</b> , 20, 642	4.8	2
263	Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 1301	3.2	3
262	Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. <i>Theranostics</i> , <b>2020</b> , 10, 11921-11937	12.1	7
261	Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. <i>EBioMedicine</i> , <b>2020</b> , 62, 103107	8.8	6
260	Association of intrinsic pathways with altered tumor immune infiltration in hepatocellular carcinoma: New targets for combining immune therapy. <i>Clinical and Translational Medicine</i> , <b>2020</b> , 10, e219	5.7	0
259	2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. <i>Hepatobiliary Surgery and Nutrition</i> , <b>2020</b> , 9, 452-463	2.1	87
258	Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study. <i>Clinical and Translational Medicine</i> , <b>2020</b> , 10, e137	5.7	11
257	Genetic Alterations and Transcriptional Expression of mA RNA Methylation Regulators Drive a Malignant Phenotype and Have Clinical Prognostic Impact in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 900	5.3	3
256	Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 573	9.8	24
255	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 895	9.8	3
254	Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients. <i>Annals of Surgery</i> , <b>2020</b> , 271, 534-541	7.8	41
253	HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 169-180	7.5	17
252	Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. <i>Carcinogenesis</i> , <b>2020</b> , 41, 296-302	4.6	37

251	Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis. <i>Carcinogenesis</i> , <b>2020</b> , 41, 950-960	4.6	4
250	Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1606-1617	7.5	17
249	Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT- $\beta$ -catenin signaling pathway. <i>Carcinogenesis</i> , <b>2020</b> , 41, 130-138	4.6	16
248	A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. <i>Genes and Diseases</i> , <b>2019</b> , 6, 419-430	6.6	18
247	Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. <i>Cell</i> , <b>2019</b> , 179, 561-577.e22	56.2	232
246	Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression. <i>Cancer Science</i> , <b>2019</b> , 110, 2133-2144	6.9	17
245	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 203	8.5	10
244	Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 5187-5195	3.6	8
243	MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. <i>Cancer Letters</i> , <b>2019</b> , 459, 156-167	9.9	25
242	Circular RNA circTRIM33-12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression. <i>Molecular Cancer</i> , <b>2019</b> , 18, 105	42.1	118
241	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. <i>BMC Medicine</i> , <b>2019</b> , 17, 106	11.4	17
240	Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. <i>Science China Life Sciences</i> , <b>2019</b> , 62, 1138-1143	8.5	14
239	EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the promoter. <i>Theranostics</i> , <b>2019</b> , 9, 2424-2438	12.1	19
238	Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , <b>2019</b> , 495, 191-197	6.2	11
237	Postoperative $\beta$ -fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis. <i>Surgery</i> , <b>2019</b> , 165, 1161-1167	3.6	7
236	Overexpression of RNF38 facilitates TGF- $\beta$ signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 113	12.8	25
235	Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. <i>Cancer Cell International</i> , <b>2019</b> , 19, 71	6.4	41
234	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110 and predicts poor prognosis. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 37	22.4	73

233	Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. <i>Carcinogenesis</i> , <b>2019</b> , 40, 1077-1085	4.6	23
232	Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. <i>BMC Cancer</i> , <b>2019</b> , 19, 335	4.8	7
231	A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression. <i>Hepatology</i> , <b>2019</b> , 70, 1214-1230	11.2	75
230	Predicting overall survival of patients with hepatocellular carcinoma using a three-category method based on DNA methylation and machine learning. <i>Journal of Cellular and Molecular Medicine</i> , <b>2019</b> , 23, 3369-3374	5.6	16
229	Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3304-3316	12.9	57
228	A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. <i>Cancer Letters</i> , <b>2019</b> , 450, 98-109	9.9	55
227	CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. <i>Hepatology</i> , <b>2019</b> , 69, 143-159	11.2	61
226	A novel very simple laparoscopic hepatic inflow occlusion apparatus for laparoscopic liver surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2019</b> , 33, 145-152	5.2	4
225	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , <b>2019</b> , 10, 3914-3925	4.5	20
224	Surgical Resection plus Radiofrequency Ablation versus Radical Surgery for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , <b>2019</b> , 10, 3933-3940	4.5	3
223	The miR-561-5p/CXCL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CXCR1 Natural Killer Cells Infiltration. <i>Theranostics</i> , <b>2019</b> , 9, 4779-4794	12.1	43
222	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. <i>Theranostics</i> , <b>2019</b> , 9, 4678-4687	12.1	36
221	Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. <i>BMC Cancer</i> , <b>2019</b> , 19, 760	4.8	43
220	Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications. <i>Clinical and Translational Gastroenterology</i> , <b>2019</b> , 10, e00006	4.2	19
219	Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1152-1163	13.4	28
218	Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 1369-1378	7.4	8
217	Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. <i>Gut</i> , <b>2019</b> , 68, 2195-2205	19.2	99
216	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. <i>Cancer Medicine</i> , <b>2019</b> , 8, 6933-6944	4.8	6

215	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. <i>Journal of Cancer</i> , <b>2019</b> , 10, 5575-5584	4.5	12
214	Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005). <i>Pediatric Hematology and Oncology</i> , <b>2019</b> , 36, 399-409	1.7	4
213	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. <i>Aging</i> , <b>2019</b> , 11, 11111-11123	5.6	5
212	eIF3a mediates HIF1 $\beta$ -dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation. <i>American Journal of Cancer Research</i> , <b>2019</b> , 9, 1079-1090	4.4	6
211	Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , <b>2019</b> , 9, 2442-2455	4.4	9
210	International consensus statement on robotic hepatectomy surgery in 2018. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 1432-1444	5.6	67
209	High spatiotemporal heterogeneity, clonal selection and neoantigen evolution in acquired sorafenib-resistant patient-derived xenograft models of hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15641-e15641	2.2	
208	Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. <i>Nature</i> , <b>2019</b> , 567, 257-261	50.4	314
207	Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , <b>2019</b> , 8, 19-28	2.1	8
206	Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion. <i>Oncologist</i> , <b>2019</b> , 24, 513-520	5.7	21
205	Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , <b>2019</b> , 8, 582-596	2.1	9
204	Differential network analysis depicts regulatory mechanisms for hepatocellular carcinoma from diverse backgrounds. <i>Future Oncology</i> , <b>2019</b> , 15, 3917-3934	3.6	1
203	Laparoscopic Versus Open Left Lateral Segmentectomy for Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , <b>2019</b> , 29, 513-519	1.3	5
202	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. <i>Oncologist</i> , <b>2019</b> , 24, 997-1007	5.7	6
201	Mechanisms involved in the activation of C/EBP $\beta$ by small activating RNA in hepatocellular carcinoma. <i>Oncogene</i> , <b>2019</b> , 38, 3446-3457	9.2	16
200	Dexamethasone for postoperative hyperbilirubinemia in patients after liver resection: An open-label, randomized controlled trial. <i>Surgery</i> , <b>2019</b> , 165, 534-540	3.6	3
199	NMethyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. <i>Nature Chemical Biology</i> , <b>2019</b> , 15, 88-94	11.7	149
198	The long noncoding RNA NORAD enhances the TGF- $\beta$ pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 12051-12060	7	32

197	Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 725-736	4.9	28
196	Differentially expressed miRNAs in hepatocellular carcinoma cells under hypoxic conditions are associated with transcription and phosphorylation. <i>Oncology Letters</i> , <b>2018</b> , 15, 467-474	2.6	10
195	CK7/CK19 index: A potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 117, 1531-1539	2.8	23
194	Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study. <i>Cancer</i> , <b>2018</b> , 124, 2161-2168	6.4	20
193	AGO1 may influence the prognosis of hepatocellular carcinoma through TGF- $\beta$ pathway. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 324	9.8	23
192	The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. <i>Nature Communications</i> , <b>2018</b> , 9, 1572	17.4	116
191	New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 117, 1540-1547	2.8	34
190	Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 1686-1694 <sup>3,1</sup>	3.1	22
189	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2203-2213	12.9	59
188	Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2074-2081	12.9	84
187	42,573 cases of hepatectomy in China: a multicenter retrospective investigation. <i>Science China Life Sciences</i> , <b>2018</b> , 61, 660-670	8.5	30
186	Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. <i>Cell Research</i> , <b>2018</b> , 28, 359-373	24.7	60
185	Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression. <i>Cell</i> , <b>2018</b> , 173, 634-648.e12	56.2	65
184	Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 89-98	13.4	33
183	MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. <i>Cancer Letters</i> , <b>2018</b> , 412, 108-117	9.9	59
182	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 547-559	12.9	72
181	Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult. <i>Cancer Research</i> , <b>2018</b> , 78, 5548-5560	10.1	32
180	Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy. <i>Theranostics</i> , <b>2018</b> , 8, 2329-2347	12.1	80

179	Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. <i>Nature</i> , <b>2018</b> , 559, 637-641	50.4	210
178	Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study. <i>Journal of Cancer</i> , <b>2018</b> , 9, 148-156	4.5	13
177	Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 935-945	4.2	10
176	NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 28	22.4	23
175	microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 535	9.8	29
174	PDXliver: a database of liver cancer patient derived xenograft mouse models. <i>BMC Cancer</i> , <b>2018</b> , 18, 550	4.8	13
173	Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 2098-2104	3.1	23
172	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , <b>2018</b> , 9, 1106-1112	4.5	11
171	Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1 $\alpha$ in lung cancer. <i>Theranostics</i> , <b>2018</b> , 8, 4050-4061	12.1	35
170	Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Oncology Research</i> , <b>2018</b> , 26, 231-239	4.8	17
169	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). <i>Liver Cancer</i> , <b>2018</b> , 7, 235-260	9.1	291
168	Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4. <i>American Journal of Cancer Research</i> , <b>2018</b> , 8, 1040-1049	4.4	10
167	Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. <i>American Journal of Translational Research (discontinued)</i> , <b>2018</b> , 10, 3567-3578	3	5
166	CD13-HDAC5 signaling axis promotes hepatocellular carcinoma and sorafenib resistance by activating NF- $\kappa$ B. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e16144-e16144	2.2	
165	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. <i>Gastroenterology</i> , <b>2018</b> , 154, 128-139	13.3	234
164	A novel and validated prognostic nomogram based on liver fibrosis and tumor burden for patients with hepatocellular carcinoma after curative resection. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 117, 625-633	2.8	11
163	Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. <i>BMC Cancer</i> , <b>2018</b> , 18, 1148	4.8	68
162	Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child-Pugh I who underwent curative resection: a prognostic nomogram study. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5383-5394	3.6	7

161	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. <i>Theranostics</i> , <b>2018</b> , 8, 5690-5702	12.1	33
160	miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 294	12.8	46
159	Long non-coding RNA 00607 as a tumor suppressor by modulating NF- $\kappa$ B p65/p53 signaling axis in hepatocellular carcinoma. <i>Carcinogenesis</i> , <b>2018</b> , 39, 1438-1446	4.6	20
158	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 1036	9.8	18
157	Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , <b>2018</b> , 23, 1482-1493	5.7	18
156	Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging. <i>Molecular Therapy - Nucleic Acids</i> , <b>2018</b> , 13, 376-386	10.7	17
155	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. <i>Journal of Cancer</i> , <b>2018</b> , 9, 1025-1032	4.5	13
154	Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. <i>Journal of Integrative Medicine</i> , <b>2018</b> , 16, 236-248	4	46
153	DNMT1 mediates metabolic reprogramming induced by Epstein-Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 619	9.8	43
152	Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. <i>Oncology Letters</i> , <b>2018</b> , 15, 8396-8404	2.6	10
151	Predictive gene-expression score for follicular lymphoma. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e278	21.7	
150	Autophagy activation contributes to glutathione transferase Mu 1-mediated chemoresistance in hepatocellular carcinoma. <i>Oncology Letters</i> , <b>2018</b> , 16, 346-352	2.6	8
149	Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. <i>Hepatology</i> , <b>2017</b> , 65, 1948-1962	11.2	28
148	Long noncoding RNA SchLAH suppresses metastasis of hepatocellular carcinoma through interacting with fused in sarcoma. <i>Cancer Science</i> , <b>2017</b> , 108, 653-662	6.9	39
147	Novel role of semaphorin3A in the growth and progression of hepatocellular carcinoma. <i>Oncology Reports</i> , <b>2017</b> , 37, 3313-3320	3.5	10
146	Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , <b>2017</b> , 21, 1471-1479	3.3	25
145	Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. <i>Oncologist</i> , <b>2017</b> , 22, 561-569	5.7	27
144	Hepatic IFIT3 predicts interferon- $\alpha$ therapeutic response in patients of hepatocellular carcinoma. <i>Hepatology</i> , <b>2017</b> , 66, 152-166	11.2	38

143	Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 293-301	13.4	58
142	Neolbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. <i>Molecular Carcinogenesis</i> , <b>2017</b> , 56, 1414-1426	5	31
141	A New Preoperative Prognostic System Combining CRP and CA199 For Patients with Intrahepatic Cholangiocarcinoma. <i>Clinical and Translational Gastroenterology</i> , <b>2017</b> , 8, e118	4.2	21
140	Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 3843-3851	4.4	87
139	Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. <i>Journal of Cancer</i> , <b>2017</b> , 8, 3862-3867	4.5	21
138	The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 5363-5375	4.4	7
137	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. <i>BMC Cancer</i> , <b>2017</b> , 17, 762	4.8	12
136	STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. <i>Molecular Cancer</i> , <b>2017</b> , 16, 136	42.1	289
135	Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. <i>Oncotarget</i> , <b>2017</b> , 8, 1774-1787	3.3	13
134	Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. <i>BioScience Trends</i> , <b>2017</b> , 11, 469-474	9.9	3
133	Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. <i>Journal of Cancer</i> , <b>2017</b> , 8, 1338-1346	4.5	10
132	Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. <i>Oncotarget</i> , <b>2017</b> , 8, 13293-13303	3.3	30
131	Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection. <i>Chinese Medical Journal</i> , <b>2017</b> , 130, 2650-2660	2.9	12
130	Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. <i>Oncotarget</i> , <b>2017</b> , 8, 113817-113827	3.3	19
129	Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , <b>2017</b> , 6, 387-396	2.1	43
128	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 47121-47135	3.3	23
127	Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma. <i>Journal of Pathology</i> , <b>2017</b> , 243, 407-417	9.4	13
126	FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF- $\beta$ /Smad2/3 signaling pathway. <i>BMC Cancer</i> , <b>2017</b> , 17, 648	4.8	23



125	Salvage transhepatic arterial embolization after failed stage I ALPPS in a patient with a huge HCC with chronic liver disease: A case report. <i>International Journal of Surgery Case Reports</i> , <b>2017</b> , 39, 131-135	0.8	9
124	A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections. <i>Lipids in Health and Disease</i> , <b>2017</b> , 16, 123	4.4	8
123	Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. <i>BMC Cancer</i> , <b>2017</b> , 17, 58	4.8	26
122	Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , <b>2017</b> , 12, 28	3.5	1
121	MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis. <i>Cell Death and Disease</i> , <b>2017</b> , 8, e2906	9.8	48
120	Serum gamma-glutamyl transferase levels affect the prognosis of patients with intrahepatic cholangiocarcinoma who receive postoperative adjuvant transcatheter arterial chemoembolization: A propensity score matching study. <i>International Journal of Surgery</i> , <b>2017</b> , 37, 24-28	7.5	9
119	Circulating CD14 HLA-DR myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. <i>Hepatology Research</i> , <b>2017</b> , 47, 1061-1071	5.1	42
118	Donor liver steatosis: A risk factor for early new-onset diabetes after liver transplantation. <i>Journal of Diabetes Investigation</i> , <b>2017</b> , 8, 181-187	3.9	18
117	Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents. <i>Gastroenterology</i> , <b>2017</b> , 152, 232-242.e4	13.3	81
116	Long non-coding RNA00364 represses hepatocellular carcinoma cell proliferation via modulating p-STAT3-IFIT2 signaling axis. <i>Oncotarget</i> , <b>2017</b> , 8, 102006-102019	3.3	28
115	Whole-Exome Sequencing-Based Mutational Profiling of Hepatitis B Virus-Related Early-Stage Hepatocellular Carcinoma. <i>Gastroenterology Research and Practice</i> , <b>2017</b> , 2017, 2029315	2	11
114	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. <i>Oncotarget</i> , <b>2017</b> , 8, 5135-5148	3.3	24
113	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , <b>2017</b> , 7, 2465-2477	4.4	5
112	Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. <i>Laboratory Investigation</i> , <b>2017</b> , 97, 1201-1217	5.9	12
111	Robotic procedure versus open surgery for simultaneous resection of colorectal cancer with liver metastases: Short-term outcomes of a randomized controlled study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3575-3575	2.2	
110	PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection. <i>Tumor Biology</i> , <b>2016</b> , 37, 2987-98	2.9	26
109	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2016</b> , 40, 169-78	2.4	25
108	Circulating Fibroblast Growth Factor 21 Is A Sensitive Biomarker for Severe Ischemia/reperfusion Injury in Patients with Liver Transplantation. <i>Scientific Reports</i> , <b>2016</b> , 6, 19776	4.9	15

107	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. <i>International Journal of Oncology</i> , <b>2016</b> , 49, 2367-2376	4.4	27
106	Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma. <i>Scientific Reports</i> , <b>2016</b> , 6, 28229	4.9	2
105	EBV-LMP1 suppresses the DNA damage response through DNA-PK/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma. <i>Cancer Letters</i> , <b>2016</b> , 380, 191-200	9.9	59
104	Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase. <i>Cancer Research</i> , <b>2016</b> , 76, 5743-5755	10.1	69
103	The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined. <i>World Journal of Surgical Oncology</i> , <b>2016</b> , 14, 131	3.4	16
102	miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. <i>Hepatology</i> , <b>2016</b> , 63, 1560-75	11.2	137
101	Naive Treg-like CCR7(+) mononuclear cells indicate unfavorable prognosis in hepatocellular carcinoma. <i>Tumor Biology</i> , <b>2016</b> , 37, 9909-17	2.9	3
100	Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 767-76	8.7	50
99	Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. <i>Gastroenterology</i> , <b>2016</b> , 150, 1646-1658. <sup>13, 238</sup>	13.3	338
98	A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma. <i>Tumor Biology</i> , <b>2016</b> , 37, 5039-47	2.9	16
97	Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis. <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 722-32	6.9	15
96	MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 87246-87256	3.3	21
95	Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. <i>American Journal of Cancer Research</i> , <b>2016</b> , 6, 577-86	4.4	17
94	A microRNA-based prediction model for lymph node metastasis in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 3587-98	3.3	20
93	Generation and characterization of a tetraspanin CD151/integrin $\beta 1$ -binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. <i>Oncotarget</i> , <b>2016</b> , 7, 6314-22	3.3	11
92	Downregulation and pro-apoptotic effect of hypoxia-inducible factor 2 alpha in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 34571-81	3.3	17
91	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 6281-6290	4.4	5
90	Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. <i>Oncotarget</i> , <b>2016</b> , 7, 2867-77	3.3	35

89	Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection. <i>Oncotarget</i> , <b>2016</b> , 7, 51733-51746	3.3	23
88	Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. <i>Journal of Cancer</i> , <b>2016</b> , 7, 1798-1803	4.5	43
87	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. <i>Oncotarget</i> , <b>2016</b> , 7, 70654-70668	3.3	35
86	Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 58302-58314	3.3	11
85	The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT). <i>Journal of Cancer</i> , <b>2016</b> , 7, 1413-20	4.5	8
84	Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. <i>Journal of Cancer</i> , <b>2016</b> , 7, 1907-1914	4.5	62
83	Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway. <i>Oncotarget</i> , <b>2016</b> , 7, 75210-75220	3.3	21
82	Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. <i>Hepatology</i> , <b>2016</b> , 63, 499-511	11.2	281
81	Sequestosome 1/p62 Protein Is Associated with Autophagic Removal of Excess Hepatic Endoplasmic Reticulum in Mice. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 18663-74	5.4	47
80	Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation: A retrospective cohort study. <i>Journal of Diabetes</i> , <b>2016</b> , 8, 579-87	3.8	4
79	Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC. <i>Liver International</i> , <b>2016</b> , 36, 284-92	7.9	23
78	Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells. <i>Cell Reports</i> , <b>2016</b> , 17, 2979-2993	10.6	26
77	Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. <i>Cancer Biomarkers</i> , <b>2016</b> , 16, 161-9	3.8	352
76	Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance. <i>Tumor Biology</i> , <b>2016</b> , 37, 9691-8	2.9	16
75	Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma. <i>European Journal of Cancer</i> , <b>2016</b> , 62, 86-95	7.5	35
74	FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. <i>Cancer Research</i> , <b>2016</b> , 76, 4124-35	10.1	263
73	miR-612 suppresses stem cell-like property of hepatocellular carcinoma cells by modulating Sp1/Nanog signaling. <i>Cell Death and Disease</i> , <b>2016</b> , 7, e2377	9.8	36
72	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. <i>Hepatic Oncology</i> , <b>2015</b> , 2, 231-244	4	10

71	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. <i>Cancer Letters</i> , <b>2015</b> , 366, 112-22	9.9	17
70	Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma. <i>Tumor Biology</i> , <b>2015</b> , 36, 7007-15	2.9	9
69	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , <b>2015</b> , 468, 525-32	3.4	47
68	BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2015</b> , 28, 36-44	3	39
67	Multiple carcinogenesis contributes to the heterogeneity of HCC. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2015</b> , 12, 13	24.2	20
66	Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin. <i>Cancer Letters</i> , <b>2015</b> , 356, 713-20	9.9	50
65	Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 10	19.4	26
64	Establishment of monoclonal HCC cell lines with organ site-specific tropisms. <i>BMC Cancer</i> , <b>2015</b> , 15, 6784.8	4.8	10
63	Screening and Identifying a Novel ssDNA Aptamer against Alpha-fetoprotein Using CE-SELEX. <i>Scientific Reports</i> , <b>2015</b> , 5, 15552	4.9	62
62	Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epidermal growth factor receptor-induced epithelial-mesenchymal transition. <i>Hepatology</i> , <b>2015</b> , 62, 1201-14	11.2	37
61	Mitogen-activated protein kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition. <i>Hepatology</i> , <b>2015</b> , 62, 1804-16	11.2	29
60	Basal Autophagy and Feedback Activation of Akt Are Associated with Resistance to Metformin-Induced Inhibition of Hepatic Tumor Cell Growth. <i>PLoS ONE</i> , <b>2015</b> , 10, e0130953	3.7	11
59	Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. <i>International Journal of Oncology</i> , <b>2015</b> , 46, 587-96	4.4	128
58	New-onset diabetes after liver transplantation and its impact on complications and patient survival. <i>Journal of Diabetes</i> , <b>2015</b> , 7, 881-90	3.8	36
57	CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3 $\beta$ /Snail signaling. <i>Cancer Letters</i> , <b>2015</b> , 358, 124-135	9.9	127
56	Prediction of Post-Operative Liver Dysfunction by Serum Markers of Liver Fibrosis in Hepatocellular Carcinoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140932	3.7	14
55	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 846-61	3.3	67
54	Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 2538-48	3.3	44

53	Neolbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNF $\alpha$ and ROS production. <i>Oncotarget</i> , <b>2015</b> , 6, 1995-2008	3.3	60
52	Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 450-7	4.4	18
51	LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2015</b> , 8, 3892-900	1.4	9
50	miR-504 mediated down-regulation of nuclear respiratory factor 1 leads to radio-resistance in nasopharyngeal carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 15995-6018	3.3	45
49	Robot-assisted one-stage resection of rectal cancer with liver and lung metastases. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 2848-53	5.6	16
48	MiR-302c inhibits tumor growth of hepatocellular carcinoma by suppressing the endothelial-mesenchymal transition of endothelial cells. <i>Scientific Reports</i> , <b>2014</b> , 4, 5524	4.9	60
47	HNRNPAB induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by transcriptionally activating SNAIL. <i>Cancer Research</i> , <b>2014</b> , 74, 2750-62	10.1	72
46	Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma. <i>Surgery</i> , <b>2014</b> , 156, 651-60	3.6	25
45	High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2014</b> , 33, 32	12.8	29
44	Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4794-805	12.9	71
43	Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF-1 $\alpha$ expression in vivo. <i>Molecular Medicine Reports</i> , <b>2014</b> , 10, 585-92	2.9	5
42	Chinese water-pipe smoking and the risk of COPD. <i>Chest</i> , <b>2014</b> , 146, 924-931	5.3	43
41	Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e87505	3.7	21
40	Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. <i>Oncotarget</i> , <b>2014</b> , 5, 7820-32	3.3	49
39	Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6212-22	12.9	506
38	Prognostic significance of nuclear RNA export factor 3 in hepatocellular carcinoma. <i>Oncology Letters</i> , <b>2014</b> , 7, 641-646	2.6	4
37	Hepatic RIG-I predicts survival and interferon- $\gamma$ therapeutic response in hepatocellular carcinoma. <i>Cancer Cell</i> , <b>2014</b> , 25, 49-63	24.3	147
36	Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. <i>Gastroenterology</i> , <b>2014</b> , 146, 1397-407	13.3	92

35	MiR-612 suppresses the stemness of liver cancer via Wnt/ $\beta$ -catenin signaling. <i>Biochemical and Biophysical Research Communications</i> , <b>2014</b> , 447, 210-5	3-4	70
34	Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients. <i>PLoS ONE</i> , <b>2014</b> , 9, e96860	3-7	16
33	Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastases. <i>PLoS ONE</i> , <b>2014</b> , 9, e105747	3-7	19
32	RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF- $\kappa$ B-mediated epithelial-mesenchymal transition. <i>PLoS ONE</i> , <b>2014</b> , 9, e108507	3-7	27
31	RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo. <i>Oncotarget</i> , <b>2014</b> , 5, 11604-19	3-3	41
30	In vitro and clinical study of association between macrophage and epithelial-mesenchymal transition in hepatocellular carcinoma cells.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15149-e15149	2-2	
29	The biological characteristics and kinetics of circulating tumor cells in hepatocellular carcinoma undergoing surgical interventions.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e22013-e22013	2-2	
28	Effect of HnRNPAB on epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by transcriptionally activating snail.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e22004-e22004	2-2	
27	The heterogeneity and clinical relevance of circulating tumor-initiating cells in hepatocellular carcinoma using an integrated immunomagnetic-microfluidic platform.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15132-e15132	2-2	
26	Higher intratumor than peritumor expression of DUSP6/MKP-3 is associated with recurrence after curative resection of hepatocellular carcinoma. <i>Chinese Medical Journal</i> , <b>2014</b> , 127, 1211-7	2-9	4
25	Retrospective study of hepatocellular adenomas based on the phenotypic classification system: A report from China. <i>Histology and Histopathology</i> , <b>2014</b> , 29, 243-9	1-4	4
24	MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. <i>Carcinogenesis</i> , <b>2013</b> , 34, 2071-9	4-6	93
23	First in-human intraoperative imaging of HCC using the fluorescence goggle system and transarterial delivery of near-infrared fluorescent imaging agent: a pilot study. <i>Translational Research</i> , <b>2013</b> , 162, 324-331	11	33
22	Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. <i>Hepatology</i> , <b>2013</b> , 57, 1458-68	11-2	264
21	Impact of deviated balance of regulatory and cytotoxic T cells on release and reseeding of circulating tumor cells in hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e22133-e22133 <sup>2</sup>		
20	Use of nanocurcumin to inhibit proliferation and metastases of hepatocellular carcinoma via NF- $\kappa$ B mediated matrix metalloproteinase-9 downregulation.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e22103-e22103 <sup>2</sup>		
19	Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3610-3610	2-2	
18	Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. <i>Hepatology</i> , <b>2012</b> , 56, 2242-54	11-2	226

17	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , <b>2012</b> , 8, 445-544.	4.2	2783
16	Reply to G. Cai et al. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2168-2168	2.2	11
15	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. <i>Gut</i> , <b>2010</b> , 59, 953-62	19.2	206
14	CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5518-27	12.9	106
13	Lectin-based glycoproteomics to explore and analyze hepatocellular carcinoma-related glycoprotein markers. <i>Electrophoresis</i> , <b>2009</b> , 30, 2957-2966	3.6	65
12	Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2009</b> , 135, 1403-12	4.9	80
11	Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3850-9	12.9	133
10	Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2008</b> , 134, 1155-63	4.9	141
9	Three-Grade Criteria of radical resection for primary liver cancer. <i>Chinese Journal of Clinical Oncology</i> , <b>2005</b> , 2, 820-823		
8	Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 1215-9	5.6	58
7	A decade's studies on metastasis of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2004</b> , 130, 187-96	4.9	376
6	Hepatocellular carcinoma associated with tumor thrombosis in the portal vein: the effects of different treatments. <i>Hepatobiliary and Pancreatic Diseases International</i> , <b>2003</b> , 2, 513-9	2.1	11
5	The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2001</b> , 127, 559-64	4.9	12
4	Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. <i>World Journal of Gastroenterology</i> , <b>2001</b> , 7, 28-32	5.6	63
3	Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2000</b> , 126, 57-61	4.9	72
2	Multimodality treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1998</b> , 13, S315-S319	4	4
1	Multimodality treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1998</b> , 13, S315-S319	4	2